# Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Organization · id `cardio:org-bayer-healthcare-pharmaceuticals-inc-bayer-schering-pharma` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Bayer+Healthcare+Pharmaceuticals%2C+Inc.%2FBayer+Schering+Pharma>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 4 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (`cardio:ct-nct02204267`)
- Sponsors: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF (`cardio:ct-nct02387229`)
- Sponsors: A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) (`cardio:ct-nct06024746`)
- Sponsors: A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (`cardio:ct-nct06033950`)

## Provenance

Content hash: 88554e236fed22f16dc7d382f41a1bd195df8d09d6cc9ad24a08559d1860b495
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
